Rosiglitazone Decreases Bone Mass and Bone Marrow Fat

被引:52
作者
Harslof, Torben [1 ]
Wamberg, Louise [1 ]
Moller, Louise [2 ]
Stodkilde-Jorgensen, Hans [3 ]
Ringgaard, Steffen [3 ]
Pedersen, Steen B. [1 ]
Langdahl, Bente L. [1 ]
机构
[1] Aarhus Univ Hosp, Dept Endocrinol & Internal Med, THG, DK-8000 Aarhus C, Denmark
[2] Aarhus Univ Hosp, Dept Endocrinol & Internal Med, NBG, DK-8000 Aarhus C, Denmark
[3] Aarhus Univ Hosp, MR Res Ctr, DK-8200 Skejby, Denmark
关键词
PROTON MR SPECTROSCOPY; PPAR-GAMMA; MINERAL DENSITY; CONTROLLED-TRIAL; TRABECULAR BONE; ADIPOSE-TISSUE; OSTEOPOROSIS; THIAZOLIDINEDIONES; DIFFERENTIATION; CELLS;
D O I
10.1210/jc.2010-2077
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Context: Activation of peroxisome proliferator-activated receptor-gamma is believed to promote adipocyte development from mesenchymal stem cells in the bone marrow at the expense of osteoblasts, leading to decreased bone mineral density (BMD) and increased marrow fat. Objective: The objective of the study was to examine the effect of the peroxisome proliferator-activated receptor-gamma agonist, rosiglitazone, on BMD assessed by dual-energy x-ray absorptiometry in 53 healthy postmenopausal women and spine bone marrow fat assessed by magnetic resonance imaging proton spectroscopy. Design: This was a 14-wk prospective, double-blind, randomized, placebo-controlled trial. Setting: The study was conducted in the general community. Patients: Fifty-three healthy postmenopausal women participated in the study. Intervention: Intervention included rosiglitazone tablets of 8 mg/d. Main Outcome Measures: The primary end point was a change in BMD. Results: At the femoral neck, BMD decreased by 1.34 +/- 0.60% (mean +/- SEM) in the rosiglitazone group, whereas BMD increased by 0.28 +/- 0.56% in the placebo group (P = 0.055). At the lumbar spine, BMD decreased by 1.03 +/- 0.34% in the rosiglitazone group and 0.42 +/- 0.35% in the placebo group (P = 0.22). The bone resorption marker carboxy-terminal telopeptide increased by 20.4 +/- 7.7% (mean +/- SEM) in the rosiglitazone group and decreased by 7.1 +/- 4.7% in the placebo group (P = 0.003). Spine fat decreased by 13.5 +/- 5.5% (mean +/- SEM) in the rosiglitazone group and increased by 6.8 +/- 7.4% in the placebo group (P = 0.056). Conclusions: Contrary to what was expected, spine fat decreased during rosiglitazone treatment. Furthermore, rosiglitazone treatment resulted in uncoupling of bone resorption and formation leading to bone loss. Our data suggest that the bone marrow osteoblast-adipocyte relationship is more complex than was assumed and that the two cell types can be independently affected. (J Clin Endocrinol Metab 96: 1541-1548, 2011)
引用
收藏
页码:1541 / 1548
页数:8
相关论文
共 39 条
[1]   Strain-Specific Effects of Rosiglitazone on Bone Mass, Body Composition, and Serum Insulin-Like Growth Factor-I [J].
Ackert-Bicknell, Cheryl L. ;
Shockley, Keith R. ;
Horton, Lindsay G. ;
Lecka-Czernik, Beata ;
Churchill, Gary A. ;
Rosen, Clifford J. .
ENDOCRINOLOGY, 2009, 150 (03) :1330-1340
[2]  
Ahdjoudj S, 2004, HISTOL HISTOPATHOL, V19, P151, DOI 10.14670/HH-19.151
[3]   PPARγ insufficiency enhances osteogenesis through osteoblast formation from bone marrow progenitors [J].
Akune, T ;
Ohba, S ;
Kamekura, S ;
Yamaguchi, M ;
Chung, UI ;
Kubota, N ;
Terauchi, Y ;
Harada, Y ;
Azuma, Y ;
Nakamura, K ;
Kadowaki, T ;
Kawaguchi, H .
JOURNAL OF CLINICAL INVESTIGATION, 2004, 113 (06) :846-855
[4]   Rosiglitazone causes bone loss in mice by suppressing osteoblast differentiation and bone formation [J].
Ali, AA ;
Weinstein, RS ;
Stewart, SA ;
Parfitt, AM ;
Manolagas, SC ;
Jilka, RL .
ENDOCRINOLOGY, 2005, 146 (03) :1226-1235
[5]   A New Concept Underlying Stem Cell Lineage Skewing That Explains the Detrimental Effects of Thiazolidinediones on Bone [J].
Bruedigam, Claudia ;
Eijken, Marco ;
Koedam, Marijke ;
van de Peppel, Jeroen ;
Drabek, Ksenija ;
Chiba, Hideki ;
van Leeuwen, Johannes P. T. M. .
STEM CELLS, 2010, 28 (05) :916-927
[6]   Reciprocal relation between marrow adiposity and the amount of bone in the axial and appendicular skeleton of young adults [J].
Di Iorgi, Natascia ;
Rosol, Michael ;
Mittelman, Steven D. ;
Gilsanz, Vicente .
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 2008, 93 (06) :2281-2286
[7]   NORMAL AND PATHOLOGICAL REMODELING OF HUMAN TRABECULAR BONE - 3-DIMENSIONAL RECONSTRUCTION OF THE REMODELING SEQUENCE IN NORMALS AND IN METABOLIC BONE-DISEASE [J].
ERIKSEN, EF .
ENDOCRINE REVIEWS, 1986, 7 (04) :379-408
[8]  
Garnero P., 2004, Journal of Musculoskeletal & Neuronal Interactions, V4, P50
[9]  
Gimble JM, 1996, MOL PHARMACOL, V50, P1087
[10]   Association of pioglitazone treatment with decreased bone mineral density in obese premenopausal patients with polycystic ovary syndrome: A randomized, placebo-controlled trial [J].
Glintborg, Dorte ;
Andersen, Marianne ;
Hagen, Claus ;
Heickendorff, Lene ;
Hermann, Anne Pernille .
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 2008, 93 (05) :1696-1701